ERIS vs IPCALAB: Stock Comparison

ERIS LIFESCIENCES vs IPCA LABORATORIESUpdated 11 Sept 26, 4:08 PM ISTNSE & company filings

IPCA LABORATORIES is the larger company by market capitalisation. ERIS LIFESCIENCES shows a lower P/E, a higher dividend yield and faster revenue growth, while IPCA LABORATORIES shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

ERIS leads 8; IPCALAB leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

ERISIPCALAB

Valuation lens

What price are you paying?

Market CapContext only
₹18,777 Cr
₹49,905 Cr
P/E RatioERIS has the lower reading
28.98x
38.1x
P/B RatioERIS has the lower reading
4.81x
6.19x
EPSIPCALAB has the higher reading
₹10.28
₹14.71
Book ValueContext only
₹281.12
₹375.4
Dividend YieldERIS has the higher reading
0.53%
0.31%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
IPCALAB is the larger company
₹49,905 Cr vs ₹18,777 Cr
P/E Ratio
ERIS has a lower P/E
28.98x vs 38.1x
P/B Ratio
ERIS has a lower P/B
4.81x vs 6.19x
EPS
IPCALAB has higher earnings per share
₹14.71 vs ₹10.28
Dividend Yield
ERIS has a higher dividend yield
0.53% vs 0.31%
Revenue Growth (TTM YoY)
ERIS has faster revenue growth
7.1% vs 6.2%
EPS Growth (TTM YoY)
IPCALAB has faster EPS growth
341.6% vs 200%
Qtr Sales Growth
ERIS has stronger quarterly sales growth
96.68% vs -23.99%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricERISIPCALAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricERISIPCALAB
Live Price₹1,355.5₹1,968.5
Day Change-0.08%-0.12%
Volume24,9681.76 L
52-Week High₹1,740₹2,001.5
52-Week Low₹1,200₹1,251.6
Distance from 52W High-22.1%-1.65%

Valuation

MetricERISIPCALAB
Market Cap₹18,777 Cr₹49,905 Cr
P/E Ratio28.98x38.1x
P/B Ratio4.81x6.19x
EPS₹10.28₹14.71
Book Value₹281.12₹375.4
Dividend Yield0.53%0.31%

Growth

MetricERISIPCALAB
Revenue Growth (TTM YoY)7.1%6.2%
EPS Growth (TTM YoY)200%341.6%
Qtr Sales Growth96.68%-23.99%
Qtr Profit Growth196.73%-12.02%

Profitability & Leverage

MetricERISIPCALAB
ROE7.64%14.19%
ROCE6.96%14.74%
Net Margin19.89%11.83%
Operating Margin29.73%21.48%
Debt to Equity0.65x0.03x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricERISIPCALAB
Promoter Holding54.14% 0.22 pp44.72%
FII Holding5.75% 0.64 pp10.73% 0.1 pp
DII Holding20.72% 0.37 pp37.37% 0.08 pp
Public Holding19.4% 0.07 pp7.18% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ERIS LIFESCIENCES and IPCA LABORATORIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.